Guangdong Marubi Biotechnology Co (SHSE:603983) Cyclically Adjusted Revenue per Share: ¥5.85 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603983 Guangdong Marubi Biotechnology Co Ltd SHSE:603983
79 GF Score
Price ¥26.26
GF Value ¥45.61
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Guangdong Marubi Biotechnology Co Cyclically Adjusted Revenue per Share?

Guangdong Marubi Biotechnology Co SHSE:603983 -1.87% 79 Cyclically Adjusted Revenue per Share is ¥5.85 as of Mar. 2026. GuruFocus rates SHSE:603983 with a GF Score™ of 79/100 and a GF Value™ of ¥45.61 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Guangdong Marubi Biotechnology Co's adjusted revenue per share for the three months ended in Mar. 2026 was ¥2.181. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥5.85 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-24), Guangdong Marubi Biotechnology Co's current stock price is ¥26.26. Guangdong Marubi Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥5.85. Guangdong Marubi Biotechnology Co's Cyclically Adjusted PS Ratio of today is 4.49.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guangdong Marubi Biotechnology Co was 5.43. The lowest was 3.80. And the median was 4.26.


Guangdong Marubi Biotechnology Co  (SHSE:603983) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Guangdong Marubi Biotechnology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=26.26/5.85
=4.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guangdong Marubi Biotechnology Co was 5.43. The lowest was 3.80. And the median was 4.26.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Guangdong Marubi Biotechnology Co Cyclically Adjusted Revenue per Share Related Terms


Guangdong Marubi Biotechnology Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Guangdong Marubi Biotechnology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangdong Marubi Biotechnology Co Cyclically Adjusted Revenue per Share Chart

Guangdong Marubi Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Guangdong Marubi Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.85

SHSE:603983 vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Guangdong Marubi Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangdong Marubi Biotechnology Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Guangdong Marubi Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Guangdong Marubi Biotechnology Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603983
79GF Score
Guangdong Marubi Biotechnology Co Ltd SHSE:603983
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangdong Marubi Biotechnology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Guangdong Marubi Biotechnology Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.181/116.3033*116.3033
=2.181

Current CPI (Mar. 2026) = 116.3033.

Guangdong Marubi Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201112 0.000 92.885 0.000
201212 0.000 95.237 0.000
201312 0.000 97.624 0.000
201412 0.000 99.000 0.000
201512 0.000 100.600 0.000
201612 0.000 102.600 0.000
201712 0.000 104.500 0.000
201803 0.943 105.300 1.042
201806 1.074 104.900 1.191
201809 1.755 106.600 1.915
201812 1.396 106.500 1.525
201903 1.001 107.700 1.081
201906 1.258 107.700 1.358
201909 1.004 109.800 1.063
201912 1.500 111.200 1.569
202003 0.935 112.300 0.968
202006 1.047 110.400 1.103
202009 0.836 111.700 0.870
202012 1.541 111.500 1.607
202103 1.009 112.662 1.042
202106 1.161 111.769 1.208
202109 0.640 112.215 0.663
202112 1.698 113.108 1.746
202203 0.935 114.335 0.951
202206 1.091 114.558 1.108
202209 0.831 115.339 0.838
202212 1.399 115.116 1.413
202303 1.212 115.116 1.225
202306 1.461 114.558 1.483
202309 1.134 115.339 1.143
202312 1.796 114.781 1.820
202403 1.674 115.227 1.690
202406 1.696 114.781 1.718
202409 1.532 115.785 1.539
202412 2.460 114.893 2.490
202503 2.132 115.116 2.154
202506 2.217 114.907 2.244
202509 1.766 115.471 1.779
202512 2.550 115.832 2.560
202603 2.181 116.303 2.181

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥5.85 mean?
Guangdong Marubi Biotechnology Co (SHSE:603983) has a Cyclically Adjusted Revenue per Share of ¥5.85 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guangdong Marubi Biotechnology Co and its competitors.
Is Guangdong Marubi Biotechnology Co's Cyclically Adjusted Revenue per Share too high?
Guangdong Marubi Biotechnology Co's current Cyclically Adjusted Revenue per Share is ¥5.85. Overall, Guangdong Marubi Biotechnology Co has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangdong Marubi Biotechnology Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Guangdong Marubi Biotechnology Co's Cyclically Adjusted Revenue per Share of ¥5.85 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guangdong Marubi Biotechnology Co and its competitors. Guangdong Marubi Biotechnology Co's current Cyclically Adjusted Revenue per Share is ¥5.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangdong Marubi Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Guangdong Marubi Biotechnology Co (SHSE:603983) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥45.61, compared to a current price of ¥26.26 — trading 42.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥5.85. Guangdong Marubi Biotechnology Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Guangdong Marubi Biotechnology Co (SHSE:603983), the current Cyclically Adjusted Revenue per Share is ¥5.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangdong Marubi Biotechnology Co (SHSE:603983) Overvalued in 2026?

Based on GuruFocus' analysis, Guangdong Marubi Biotechnology Co stock appears to be undervalued. The current stock price of ¥26.26 is trading 42.4% below its estimated GF Value™ of ¥45.61. GuruFocus considers Guangdong Marubi Biotechnology Co to be Significantly Undervalued.

Key valuation signals for SHSE:603983:

  • Cyclically Adjusted Revenue per Share: ¥5.85
  • GF Value™: ¥45.61 vs. price of ¥26.26 (42.4% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603983 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangdong Marubi Biotechnology Co Business Description

Address No. 92, Peihe Road, Building 2, Science City, High-tech Industrial Development Zone, Guangdong Province, Guangzhou, CHN, 510000
Guangdong Marubi Biotechnology Co Ltd is engaged in the research and development, design, production, sales and service of various types of cosmetics.
79GF Score

Get the complete analysis for SHSE:603983

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.26
Price
¥45.61
GF Value